SN-38 Size:Solid 2 mg Emerging evidence suggests that it

Emerging evidence suggests that it possesses efficacy in treating a number of viral infections as well

though it may also have an anti-angiogenic effect

InChiKey: UBQNRHZMVUUOMG-UHFFFAOYSA-N

WEHI-539 not only binds very tightly to BCL-XL

cyclin D1 protein expression

SN-38 Size:Solid 2 mg Emerging evidence suggests that itSN 38 is the active metabolite of irinotecan (an analog of camptothecin a topoisomerase I inhibitor); it is 1000 times more active than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN 38 relative to irinotecan varies from 2 to 2000 fold. SN38 is metabolized via glucoronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolization of irinotecan predicts irinotecan toxicity, as it cannot be